Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Takeda Pharmaceuticals Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (115)
Cancellation by sponsor (61)
Prescription medicine registration (16)
Australian public assessment report (AusPar) (13)
Designation or determination (7)
Prescription medicine decision summary (4)

Date

2026 (12)
2025 (3)
2024 (31)
2023 (7)
2022 (14)
2021 (14)
2020 (13)
2019 (17)
2018 (6)
2017 (34)
2016 (5)
2015 (5)
2014 (14)
2013 (11)
2012 (3)
2010 (1)
2009 (2)
2008 (8)
2007 (2)
2006 (1)
2005 (9)
2002 (1)
2000 (2)
1999 (1)

Search

Sponsor content

216 result(s) found, displaying 151 to 160

NESINA PIO 12.5/15 12.5 mg alogliptin (as benzoate) / 15 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Cancelled under s30(1)(c)

4 December 2017

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
ENTYVIO vedolizumab 300 mg powder for injection vial (210048)

27 June 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ENTYVIO vedolizumab 300 mg powder for injection vial.
KYNTELES vedolizumab (rch) 300 mg powder for injection vial (210042)

27 June 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for KYNTELES vedolizumab (rch) 300 mg powder for injection vial.
AusPAR: Ixazomib citrate

16 November 2017

Australian public assessment report (AusPar)

Ixazomib citrate
AusPAR: Brentuximab vedotin

11 October 2017

Australian public assessment report (AusPar)

Australian Public Assessment Report for Brentuximab vedotin
Calcia + Vitamin D 200 IU (Lemon) Cancelled under s30 (1)(c)

27 September 2017

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
Calcia + Vitamin D 400IU (Lemon) Cancelled under s30 (1)(c)

27 September 2017

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
Calcia + Vitamin D 400 IU (Orange) Cancelled under s30 (1)(c)

27 September 2017

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
Calcia 1000 (Orange) Cancelled under s30 (1)(c)

27 September 2017

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
Calcia + Vitamin D 200IU (Orange) Cancelled under s30 (1)(c)

27 September 2017

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd

Pages

First page
Previous page
…
Page 12
Page 13
Page 14
Page 15
Current page 16
Page 17
Page 18
Page 19
Page 20
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.